Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met

International Journal of Cancer

Volumn 124, Issue 8, 2009, Pages 1767-1772

  Marx Stoelting, Philip ^a   Borowiak, Malgorzata ^b,c   Knorpp, Thomas ^d   Birchmeier, Carmen ^b   Buchmann, Albrecht ^a   Schwarz, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Max Delbrüuck Zentrum   (Germany)

^c Harvard University   (United States)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

catenin; c Met; Liver; Phenobarbital; Tumour initiation; Tumour promotion

Indexed keywords

DIETHYLNITROSAMINE; PHENOBARBITAL; SCATTER FACTOR RECEPTOR; GLUCOSE 6 PHOSPHATASE; GLUTAMATE AMMONIA LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; KNOCKOUT MOUSE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; LIVER; LIVER TUMOR; METABOLISM; MOUSE MUTANT; ORGAN SIZE; PHENOTYPE; SIGNAL TRANSDUCTION; TIME;

ANIMALS; DIETHYLNITROSAMINE; GLUCOSE-6-PHOSPHATASE; GLUTAMATE-AMMONIA LIGASE; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; ORGAN SIZE; PHENOBARBITAL; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 62449088315     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24167     Document Type: Article

References (30)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925 (Pubitemid 37493640)
2. Borowiak M, Garratt AN, Wustefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004;101:10608-10613 (Pubitemid 38955789)
3. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69. (Pubitemid 39656109)
4. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF. Mechanism of met oncogene activation. Cell 1986;45:895-904. (Pubitemid 16083694)
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251: 802-804 (Pubitemid 21926175)
6. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther 2005;4:1577-1584 (Pubitemid 41556441)
7. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc Natl Acad Sci USA 1992;89:373-377
8. Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, Vandenbunder B, Fafeur V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002;21:2309-2319 (Pubitemid 34407290)
9. Santoni-Rugiu E, Preisegger KH, Kiss A, Audolfsson T, Shiota G, Schmidt EV, Thorgeirsson SS. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 1996;93:9577-9582 (Pubitemid 26296650)
10. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001;20:7812-7816 (Pubitemid 33121956)
11. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 2002;62: 2064-2071 (Pubitemid 34408453)
12. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007;45:1298-1305 (Pubitemid 46775794)
13. Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c- Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 2007;67:9844-9851 (Pubitemid 47621232)
14. Loeppen S, Koehle C, Buchmann A, Schwarz M. A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 2005;26:239-248 (Pubitemid 40207719)
15. Wachstein M, Meisel E. Histochemistry of hepatic phosphatases of a physiologic pH; with special reference to the demonstration of bile canaliculi. Am J Clin Pathol 1957;27:13-23.
16. Campbell HA, Pitot HC, Potter VR, Laishes BA. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 1982;42:465-472 (Pubitemid 12173580)
17. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2004. ISBN 3-900051-901003 Available at http://www.R-project.org.
18. Loeppen S, Schneider D, Gaunitz F, Gebhardt R, Kurek R, Buchmann A, Schwarz M. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res 2002;62:5685-5688 (Pubitemid 35204722)
19. Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers WH, Kitajewski J, Kahn A, Perret C. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002;21:8293-8301 (Pubitemid 35477869)
20. Strathmann J, Schwarz M, Tharappel JC, Glauert HP, Spear BT, Robertson LW, Appel KE, Buchmann A. PCB 153, a non-dioxin-like tumor promoter, selects for beta-catenin (Catnb)-mutated mouse liver tumors. Toxicol Sci 2006;93:34-40. (Pubitemid 44288247)
21. Luebeck EG, Buchmann A, Schneider D, Moolgavkar SH, Schwarz M. Modulation of liver tumorigenesis in Connexin32-deficient mouse. Mutat Res 2005;570:33-47. (Pubitemid 40185377)
22. Moolgavkar SH, Luebeck EG, de Gunst M, Port RE, Schwarz M. Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments-I. Single agent regimen. Carcinogenesis 1990;11:1271-1278
23. Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis.Mutat Res 2008;638:66-74.
24. Jaworski M, Buchmann A, Bauer P, Riess O, Schwarz M. B-raf and Ha-ras mutations in chemically induced mouse liver tumors. Oncogene 2005;24:1290-1295 (Pubitemid 40313931)
25. Yamamoto Y, Moore R, Goldsworthy TL, Negishi M, Maronpot RR. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004;64:7197-7200 (Pubitemid 39372050)
26. Pustylnyak VO, Zakharova LY, Mikhailova ON, Rice RH, Gulyaeva LF, Lyakhovich VV. In vivo effects of protein kinase and phosphatase inhibitors on CYP2B induction in rat liver. Toxicology 2005;207:315-322
27. Swales K, Negishi M. CAR, driving into the future. Mol Endocrinol 2004;18:1589-1598 (Pubitemid 38864783)
28. Yu LG, Packman LC, Weldon M, Hamlett J, Rhodes JM. Protein phosphatase 2A, a negative regulator of the ERK signaling pathway, is activated by tyrosine phosphorylation of putative HLA class II-associated protein I (PHAPI)/pp32 in response to the antiproliferative lectin, jacalin. J Biol Chem 2004;279:41377-41383 (Pubitemid 39313577)
29. Kakizaki S, Yamazaki Y, Kosone T, Horiguchi N, Sohara N, Sato K, Takagi H, Yoshinari K, Mori M. Gene expression profiles of drug-metabolizing enzymes and transporters with an overexpression of hepatocyte growth factor. Liver Int 2007;27:109-119 (Pubitemid 46139435)
30. Koike C, Moore R, Negishi M. Extracellular signal-regulated kinase is an endogenous signal retaining the nuclear constitutive active/androstane receptor (CAR) in the cytoplasm of mouse primary hepatocytes. Mol Pharmacol 2007;71:1217-1221 (Pubitemid 46658675)